Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
latest_posts
- 1
The Best Games On the planet - 2Argentina joins NASA’s moon return with microsatellite testing GPS beyond Earth
- 3Figure out how to Consolidate All encompassing Practices with a Degree in Brain research
- 4Find the Mysteries of Effective Objective Setting: Transforming Dreams into Feasible Targets
- 5How did this 20-light-year-wide 'Diamond Ring' form in space? Maybe a cosmic bubble burst
- Sahel coups push Africa to top of global democratic declines, report finds
- Inn The executives: A Remunerating Profession Decision for Energetic People
- 80 km. on foot: Sharren Haskel’s three-day march in protest of haredi draft bill
- Stolen Renoir, Cézanne and Matisse were probably uninsured, market sources say
- A trip to Colombia in my 20s turned into 8 years freelancing in South America. Here's what I'd do differently.
- Iranian strikes on Israel injure 11 and set chemical plant ablaze
- Boats escort freed whale away from shallow waters off German coast
- Europe could get 42 more days of summer by the year 2100 due to climate change
- Astronauts welcome arrival of new crewmates | On the International Space Station this week Nov. 24-28, 2025
